Odyssey Therapeutics, Inc. (ODTX)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$39.2M
Cash & Equivalents
$41.0M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$802M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT04919122 Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma OTHER Active Not Recruiting 468

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

FDA-Related SEC Filings

DateTypeDescriptionLink
2026-06-23 8-K Odyssey Therapeutics, Inc. (ODTX) (CIK 0001882782) - EX-99.1 EDGAR

More Analysis